电邮这篇文章 Long-term effect of 3-week intravenous б-lipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations
- 作者: Ametov A.S.1, Novosadova MV1, Barinov AN2, Samigullin R3, Tritschler H.4, Ametov AS5, Novosadova MV5, Barinov AN6, Samigullin R3, Tritschler H-.4
-
隶属关系:
- РМАПО
- Марфо-Мариинский медицинский центр "Милосердие", клиника боли
- Orthonica GmbH
- MEDA Pharma GmbH & Co. KG
- Russian Medical Academy of Postgraduate Education
- Pain Clinic, Marfo-Mariinsk Charity Medical Center
- 期: 卷 82, 编号 12 (2010)
- 页面: 61-64
- 栏目: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/30760
- ID: 30760
如何引用文章
全文:
详细
Subects and methods. The study included patients with symptoms of myodiabetic polyneuropathy. The authors studied trends in neuropathic symptoms by the TSS scale and neuropathic deficit by the NIS-LL scale after 3-week intravenous a-LA (600 mg/day) administration. Control follow-up visits were made at weeks 8 and 30 of the study.
Results. In б-LA-treated patients, the mean TSS score dropped from 9.46±1.01 to 3.29±1.49 after intravenous б-LA administration and continued to decrease to 2.60±1.18 and 4.39±2.01 scores at follow-up weeks 8 and 30, respectively. In the placebo group, these were 9.78±1.23, 6.16±1.95, 6.52±1.61, and 7.36±1.31 scores at weeks 3, 8, and 30, respectively; p < 0.05). In the б-LA group, NIS-LL scores fell from 8.65±3.46 to 6.01±3.12 at therapy week 3, to 6.11±3.36, at week 8, and to 7.68±3.68 at week 30 and in the placebo group, these decreased from 8.35±3.84 to 7.81±3.51, 7.89±3.72, and 8.32±3.49 scores at weeks 3, and 8, respectively; p < 0.05).
Conclusion. Alleviated neuropathic symptoms persisted within 6 months after 3-week intravenous б-LA injection. Reduced neuropathic deficit did within 8 weeks after initiation of б-LA therapy.
作者简介
Aleksandr Ametov
РМАПО
Email: alexander.ametov@gmail.com
Кафедра эндокринологии и диабетологии- д-р мед. наук, проф., зав. каф. эндокринологии и диабетологии РМАПО, тел.: 8-495-490-01-14- д-р мед. наук, проф., зав. каф. эндокринологии и диабетологии РМАПО, тел.: 8-495-490-01-14; РМАПО
M Novosadova
РМАПОКафедра эндокринологии и диабетологии; РМАПО
A Barinov
Марфо-Мариинский медицинский центр "Милосердие", клиника болиМарфо-Мариинский медицинский центр "Милосердие", клиника боли
R Samigullin
Orthonica GmbHOrthonica GmbH
Hans-J'rgen Tritschler
MEDA Pharma GmbH & Co. KGMEDA Pharma GmbH & Co. KG
A Ametov
Russian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate Education
M Novosadova
Russian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate Education
A Barinov
Pain Clinic, Marfo-Mariinsk Charity Medical CenterPain Clinic, Marfo-Mariinsk Charity Medical Center
R Samigullin
Orthonica GmbHOrthonica GmbH
H Tritschler
MEDA Pharma GmbH & Co. KGMEDA Pharma GmbH & Co. KG
参考
- MacDonald B. K., Cockerell O. C., Sander J. W., Shorvon S. D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-676.
- Ziegler D., Rathmann W., Dickhaus T. et al. for the KORA Study Group. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy. The MONICA/KORA Augsburg Surveys S2 and S3. Diabet. Care 2007;
- Boulton A. J. M., Vinik A. I., Arezzo J. C. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabet. Care 2005; 28: 956-962.
- Coppini D. V., Bowtell P. A., Weng C. et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J. Clin. Epidemiol. 2000; 53: 519-523.
- Daousi C., MacFarlane I. A., Woodward A. et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med. 2004; 21: 976-982.
- Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabet. Care 2006; 29: 1518-1522.
- Galer B. S., Gianas A., Jensen M. P. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabet. Res. Clin. Pract. 2000; 47: 123-128.
- Daousi C., Benbow S. J., Woodward A., MacFarlane I. A. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet. Med. 2006; 23: 1021-1024.
- Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabet. Care 2008; 31(Suppl. 2): S255-S261.
- Stracke H., Gaus W., Achenbach U. et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp. Clin. Endocrinol. Diabet. 2008;
- Ziegler D. Thioctic acid: A critical review of its effects in patients with symptomatic diabetic polyneuropathy. Treat. Endocrinol. 2004; 3: 173-189.
- Vincent A. M., Russell J. W., Low P., Feldman E. L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 2004; 25: 612-628.
- Ziegler D., Sohr C. G. H., Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and autonomic neuropathy. Diabet. Care 2004; 27: 2178-2183.
- Ziegler D., Nowak H., Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant б-lipoic acid: a meta-analysis. Diabet. Med. 2004; 21: 114-121.
- Ametov A., Barinov A., O'Brien P. et al. The sensory symptoms of diabetic polyneuropathy are improved with б-lipoic acid. The SYDNEY Trial. Diabet. Care 2003; 26: 770-776.
- Dworkin R. H., Turk D. C., Wyrwich K. W. et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT Recommendations. J. Pain 2008; 9: 105-121.
- Ziegler D., Ametov A., Barinov A. et al. Oral treatment with б-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 Trial. Diabet. Care 2006; 29: 2365-2370.
- Ziegler D., Low P. A., Boulton A. J. M. et al. Antioxidant treatment with б-lipoic acid in diabetic polyneuropathy. A 4-year randomised double-blind trial (NATHAN 1 Study). Diabetologia 2007; 50 (Suppl. 1): S 63.
补充文件
